Custom Assay Development
Custom Assay Development
Measure the biomarkers that matter
At Altheome, we offer custom assay development (CAD) using the SIMOA®, MSD® and NULISA™ platforms, enabling highly sensitive detection of protein biomarkers that are not available in standard panels.
Many research programmes require measurement of novel or emerging biomarkers beyond the scope of commercial assays.
Our custom development services allow researchers to build tailored assays designed around their specific biological questions, whether for early discovery, translational research, or clinical studies.
Measure the biomarkers that matter
At Altheome, we offer custom assay development (CAD) using the SIMOA®, MSD® and NULISA™ platforms, enabling highly sensitive detection of protein biomarkers that are not available in standard panels.
Many research programmes require measurement of novel or emerging biomarkers beyond the scope of commercial assays.
Our custom development services allow researchers to build tailored assays designed around their specific biological questions, whether for early discovery, translational research, or clinical studies.
We work closely with our partners to design assays that are fit for purpose, ensuring robust analytical performance and reliable data generation across a range of biological matrices including serum, plasma, CSF and other clinical samples.
We work closely with our partners to design assays that are fit for purpose, ensuring robust analytical performance and reliable data generation across a range of biological matrices including serum, plasma, CSF and other clinical samples.
I Want to Know More
Expertise in Nulisa-based assay design
Our team has specialised expertise developing and optimising assays within the NULISA™ workflow, enabling highly sensitive and multiplexed measurement of low-abundance protein biomarkers. Our scientific team brings extensive experience delivering custom assay development projects on NULISA™ for major charities and leading global biopharmaceutical companies.
The NULISA™ platform is particularly well suited for novel biomarker targets, exploratory panels, and pathway-focused studies, where ultra-sensitive detection and multiplex capability are critical.
Expertise in Nulisa-based assay design
Our team has specialised expertise developing and optimising assays within the NULISA™ workflow, enabling highly sensitive and multiplexed measurement of low-abundance protein biomarkers. Our scientific team brings extensive experience delivering custom assay development projects on NULISA™ for major charities and leading global biopharmaceutical companies.
The NULISA™ platform is particularly well suited for novel biomarker targets, exploratory panels, and pathway-focused studies, where ultra-sensitive detection and multiplex capability are critical.
Key advantages of the platform include:
Ultra-sensitive detection of low-abundance proteins
Ultra-sensitive detection of low-abundance proteins
Multiplex capability for targeted biomarker panels
Multiplex capability for targeted biomarker panels
Low sample volume requirements
Low sample
volume requirements
High analytical precision and reproducibility
Robust performance across clinical samples
Ultra-sensitive detection of low-abundance proteins
Multiplex capability for targeted biomarker panels
Low sample
volume requirements
High analytical precision and reproducibility
Robust performance across clinical samples
These capabilities make NULISA™ especially valuable for applications such as neurodegeneration, inflammation, immunology, metabolic biology, and rare biomarker detection.
Our Development Process
Our structured development workflow ensures assays are scientifically robust, analytically sound, and aligned with the goals of each project.
Our Development Process
Our structured development workflow ensures assays are scientifically robust, analytically sound, and aligned with the goals of each project.
Target Feasibility Assessment
Antibody Pair Selection and Screening
Assay Optimisation
Analytical Performance Evaluation
We review candidate biomarkers to evaluate biological relevance, expected concentration ranges, antibody availability, and compatibility with the chosen assay platform.
High-quality antibody pairs are identified through literature review, vendor screening, and experimental testing to ensure optimal specificity and sensitivity.
Assays are optimised for performance by refining antibody concentrations, incubation conditions, buffer composition, and assay configuration. Where required, we also assess multiplex compatibility.
Developed assays undergo analytical characterisation including: - Limit of detection and quantification - Dynamic range - Precision and reproducibility - Dilution linearity - Matrix effects and interference testing
Target Feasibility Assessment
Antibody Pair Selection and Screening
Assay Optimisation
Analytical Performance Evaluation
We review candidate biomarkers to evaluate biological relevance, expected concentration ranges, antibody availability, and compatibility with the chosen assay platform.
High-quality antibody pairs are identified through literature review, vendor screening, and experimental testing to ensure optimal specificity and sensitivity.
Assays are optimised for performance by refining antibody concentrations, incubation conditions, buffer composition, and assay configuration. Where required, we also assess multiplex compatibility.
Developed assays undergo analytical characterisation including: - Limit of detection and quantification - Dynamic range - Precision and reproducibility - Dilution linearity - Matrix effects and interference testing
Target Feasibility Assessment
We review candidate biomarkers to evaluate biological relevance, expected concentration ranges, antibody availability, and compatibility with the chosen assay platform.
Antibody Pair Selection and Screening
High-quality antibody pairs are identified through literature review, vendor screening, and experimental testing to ensure optimal specificity and sensitivity.
Assay Optimisation
Assays are optimised for performance by refining antibody concentrations, incubation conditions, buffer composition, and assay configuration. Where required, we also assess multiplex compatibility.
Analytical Performance Evaluation
Developed assays undergo analytical characterisation including:
Limit of detection and quantification
Dynamic range
Precision and reproducibility
Dilution linearity
Matrix effects and interference testing
This ensures the assay performs reliably across relevant sample types and concentration ranges.
From Discovery to Clinical Research
Once developed, assays can be integrated into targeted biomarker panels or deployed in standalone analyses across a variety of research settings, including:
From Discovery to Clinical Research
Once developed, assays can be integrated into targeted biomarker panels or deployed in standalone analyses across a variety of research settings, including:
Our experience across multiple ultra-sensitive platforms allows us to select the most appropriate technology for each biomarker and study design.
Our experience across multiple
ultra-sensitive platforms allows us to select the most appropriate technology for each biomarker and study design.
Work With Us
If your biomarker of interest is not available in commercial panels, our custom assay development services can help bring it into measurable space.
Contact us to discuss your targets and explore how NULISA-based custom assays can support your research.
If your biomarker of interest is not available in commercial panels, our custom assay development services can help bring it into measurable space.
Contact us to discuss your targets and explore how NULISA-based custom assays can support your research.
